Yes, this is an interesting dilemma and set of que
Post# of 148185
(Total Views: 288)
Posted On: 11/19/2019 10:01:01 AM
Re: Bored Lawyer #11125
Yes, this is an interesting dilemma and set of questions that it poses. Post combo HIV approval and pre-cancer approval, does HIV license partner get the benefit of off-label revenues?
My guess they would if no cancer license agreement is in place and even if one is, I'm not sure how they would be able to control this easily (haven't researched, but others previously noted that different names can be used)? IMO this provides any potential license partners to act sooner rather than later.....or the HIV partner to add the cancer pipeline also?
Personally, if human results confirm pre-clinical results, I expect BTD and AA to have cancer approval shortly after combo (sometime in 2020). As far as off-label insurance payments, someone (plavac I believe) noted that insurance companies largely follow NCCN recommendations.
My guess they would if no cancer license agreement is in place and even if one is, I'm not sure how they would be able to control this easily (haven't researched, but others previously noted that different names can be used)? IMO this provides any potential license partners to act sooner rather than later.....or the HIV partner to add the cancer pipeline also?
Personally, if human results confirm pre-clinical results, I expect BTD and AA to have cancer approval shortly after combo (sometime in 2020). As far as off-label insurance payments, someone (plavac I believe) noted that insurance companies largely follow NCCN recommendations.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼